Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C

Combined pegylated interferon and ribavirin therapy for chronic hepatitis C infection cause a wide range of side effects, including flu-like syndrome, hematological abnormalities, cardiovascular symptoms, gastrointestinal symptoms, pulmonary dysfunction, depression, and retinopathy. Interferon-alpha...

Full description

Saved in:
Bibliographic Details
Published in:The Korean journal of hepatology 2010-06, Vol.16 (2), p.187-191
Main Authors: Lee, Yun Nah, Jeong, Soung Won, Lim, Jae Hee, Ryu, Yang Seon, Jeon, Seong Ran, Kim, Sang Kyun, Jang, Jae Young, Kim, Young Seok, Kim, Boo Sung, Roh, Mi Oh
Format: Article
Language:Korean
Subjects:
Adult
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Diabetic Ketoacidosis - drug therapy
Diabetic Ketoacidosis - etiology
Drug Therapy, Combination
Female
Hepatitis C, Chronic - drug therapy
Humans
Insulin - therapeutic use
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Polyethylene Glycols - adverse effects
Polyethylene Glycols - therapeutic use
Recombinant Proteins
Ribavirin - adverse effects
Ribavirin - therapeutic use
Thyroiditis, Autoimmune - drug therapy
Thyroiditis, Autoimmune - etiology
Thyroxine - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Combined pegylated interferon and ribavirin therapy for chronic hepatitis C infection cause a wide range of side effects, including flu-like syndrome, hematological abnormalities, cardiovascular symptoms, gastrointestinal symptoms, pulmonary dysfunction, depression, and retinopathy. Interferon-alpha has been shown to be related to the development of various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, and type 1 diabetes mellitus (DM). Type 1 DM and thyroid disease respectively develop in 0.08-2.61% and 10-15% of patients treated with combined interferon-alpha and ribavirin for chronic hepatitis C. The coexistence of type 1 DM and autoimmune thyroiditis was rarely reported. We report a case of a 33-year-old female patient with chronic hepatitis C who simultaneously developed diabetic ketoacidosis and autoimmune thyroiditis after treatment with pegylated interferon-alpha 2b and ribavirin.
ISSN:1738-222X
DOI:10.3350/kjhep.2010.16.2.187